Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

NCT03112590 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT03112590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03112590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 1/2
Overall status
Completed
Start date
June 23, 2017
Completion date
February 20, 2023
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer female, breast cancer, male, her2-positive breast cancer